906536-12-7

Basic information

• Product Name: benzyl 2-((2R,4R)-1-((R)-2-((S)-2-acetamido-5-amino-5-oxopentanamido)-3-phenylpropanoyl)-4-(naphthalen-2-ylmethoxy)pyrrolidine-2-carboxamido)ethylcarbamate
• Synonyms: benzyl 2-((2R,4R)-1-((R)-2-((S)-2-acetamido-5-amino-5-oxopentanamido)-3-phenylpropanoyl)-4-(naphthalen-2-ylmethoxy)pyrrolidine-2-carboxamido)ethylcarbamate
• CAS NO: 906536-12-7
• Molecular Weight: 764.879
• Mol File: 906536-12-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: benzyl 2-((2R,4R)-1-((R)-2-((S)-2-acetamido-5-amino-5-oxopentanamido)-3-phenylpropanoyl)-4-(naphthalen-2-ylmethoxy)pyrrolidine-2-carboxamido)ethylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl 2-((2R,4R)-1-((R)-2-((S)-2-acetamido-5-amino-5-oxopentanamido)-3-phenylpropanoyl)-4-(naphthalen-2-ylmethoxy)pyrrolidine-2-carboxamido)ethylcarbamate(906536-12-7)
• EPA Substance Registry System: benzyl 2-((2R,4R)-1-((R)-2-((S)-2-acetamido-5-amino-5-oxopentanamido)-3-phenylpropanoyl)-4-(naphthalen-2-ylmethoxy)pyrrolidine-2-carboxamido)ethylcarbamate(906536-12-7)

Safety Data

• Hazardous Substances Data: 906536-12-7(Hazardous Substances Data)

Upstream product

• 18942-49-9 Boc-D-Phe-OH 
• 906536-20-7 N-(tert-butoxycarbonyl)-D-phenylalanyl-(4R)-N-({[(benzyloxy)carbonyl]amino}ethyl)-4-(2-naphthylmethoxy)-D-prolinamide 
• 906536-21-8 benzyl 2-((2R,4R)-1-((R)-2-amino-3-phenylpropanoyl)-4-(naphthalen-2-ylmethoxy)pyrrolidine-2-carboxamido)ethylcarbamate 
• 2490-97-3 N-acetyl-L-glutamine 

Downstream Products

• 906536-24-1 (S)-2-acetamido-N₁-((R)-1-((2R,4R)-2-(2-aminoethylcarbamoyl)-4-(naphthalen-2-ylmethoxy)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)pentanediamide 

Relevant articles and documents

Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic approach

The design, synthesis, and structure-activity relationships (SAR) of a series of novel proline and pyrrolidine based melanocortin receptor (MCR) agonists are described. To validate a conformationally constrained Arg-Nal dipeptide analogue strategy, we fir